As HIV testing technology advances, we have new tools and guidelines to diagnose HIV. For the latest updates from the CDC and APHL about conventional and point of care testing visit the Essential Resources page.
APLA-Shared ActionHD produced the webinar“HIV Testing Technologies: Choosing an HIV Test,” presented by Dr. Bernard M. Branson, a leading expert in the area of HIV testing. The webinar described general principles of HIV tests, provided an overview of how tests operate, addressed any limitations and misconceptions of HIV tests currently available, and discussed how the various tests differ.
CDC’s MMWR and Medscape are proud to introduce a new FREE continuing education (CE) activity that describes diagnosis delays among persons infected with HIV: Vital Signs: Human Immunodeficiency Virus Testing and Diagnosis Delays — United States. This activity is intended for infectious disease clinicians, family medicine specialists, internists, nurses, pharmacists, public health officials, and other clinicians caring for patients with or at risk for HIV infection.
The U.S. Food and Drug Administration today approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 (HIV-1) instead of three or more drugs included in standard HIV treatment.
After a year of repeal and replace efforts in Congress, enrollees and community advocates are preparing for the 2018 health care open enrollment period. With substantially higher premiums, health plan exits, uncertainty around subsidies, shorter enrollment periods, and less money being spent on advertising, 2018 is projected to present new barriers to ensuring access to healthcare.
This activity is intended for primary care physicians, ID/HIV specialists, and public health and preventive medicine specialists.
The goal of this activity is to improve recognition among primary care providers of patients who could benefit from human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) medications.
Talking to patients about HIV risk may lead to a conversation about PrEP.
DSHS encourages Texas healthcare providers to enhance efforts to prevent, diagnose and treat HIV in the wake of 16 rapidly growing clusters of HIV infections in the state.
HealthHIV invites prescribing providers (MDs, DOs, NPs, PAs) nationwide to participate in a 20-minute online focus group to discuss HIV prevention & PrEP. Friday, August 4, 2017 12:00 PM EST Providers interested in participating can register online. PrEP, for Pre-Exposure Prophylaxis, is an important tool in the fight against HIV.
Texas Medical Association (TMA) spotlighted the physician’s role in providing Pre-exposure Prophylaxis (PrEP) and provided in depth information on access to, efficacy of and target groups for PrEP. While treatment for an STD might be conversation starter about PrEP, PrEP is not just for STD clinicians. Primary care physicians, Ob/Gyn specialists, and others may all … Continue reading PrEP for HIV in Texas